Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma

References

• Jemal A, Siegel R, Xu J, . Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
   PubMed Web of Science ®Google Scholar
• Cavo M, Terragna C, Renzulli M, . Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. J Clin Oncol 2006;24:e4–e5.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, . Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106:2837–2840.
   PubMed Web of Science ®Google Scholar
• Jaksic W, Trudel S, Chang H, . Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005;23: 7069–7073.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005; 23:6339–6344.
   PubMed Web of Science ®Google Scholar
• Mulligan G, Mitsiades C, Bryant B, . Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007;109:3177–3188.
   PubMed Web of Science ®Google Scholar
• Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, . Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 2007;67:5418–5424.
   PubMed Web of Science ®Google Scholar
• Spets H, Stromberg T, Georgii-Hemming P, . Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6 (IL-6)-induced growth and survival. Eur J Haematol 2002;69:76–89.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Bloem AC, van der Spek E, . New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathway. Curr Pharm Des 2006;12:327–340.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Kamphuis MM, van Dijk M, . Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia 2003;17:211–219.
   PubMed Web of Science ®Google Scholar
• Wang HG, Reed JC. Mechanisms of Bcl-2 protein function. Histol Histopathol 1998;13:521–530.
   PubMed Web of Science ®Google Scholar
• Baliga BC, Kumar S. Role of Bcl-2 family of proteins in malignancy. Hematol Oncol 2002;20:63–74.
   PubMed Web of Science ®Google Scholar
• Pepper C, Thomas A, Hidalgo de Quintana J, . Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia—the role of Bcl-2 family dysregulation. Leuk Res 1999;23:1007–1014.
   PubMed Web of Science ®Google Scholar
• Tu Y, Renner S, Xu F, . BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res 1998;58:256–262.
   PubMed Web of Science ®Google Scholar
• Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440–442.
   PubMed Web of Science ®Google Scholar
• Wuilleme-Toumi S, Robillard N, Gomez P, . Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005;19:1248–1252.
   PubMed Web of Science ®Google Scholar
• Li M, Chen F, Clifton N, . Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect. Mol Cancer Ther 2010;9:3200–3209.
   PubMed Web of Science ®Google Scholar
• Pei XY, Dai Y, Grant S. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 2003;17:2036–2045.
   PubMed Web of Science ®Google Scholar
• Pei XY, Dai Y, Grant S. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. Mol Cancer Ther 2004;3:1513–1524.
   PubMed Web of Science ®Google Scholar
• Trudel S, Stewart AK, Li Z, . The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 2007;13:621–629.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Niesvizky R, Hohl RJ, . Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk Lymphoma 2009; 50:559–565.
   PubMed Web of Science ®Google Scholar
• Badros AZ, Goloubeva O, Rapoport AP, . Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol 2005;23:4089–4099.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, de Weerdt O, Veth G, . G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma. Leukemia 2004;18:1078–1084.
   PubMed Web of Science ®Google Scholar
• Chang H, Trieu Y, Qi X, . Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res 2007;31:779–782.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Richardson PG, Sonneveld P, . Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21:151–157.
   PubMed Web of Science ®Google Scholar
• Sagaster V, Ludwig H, Kaufmann H, . Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007;21: 164–168.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson J, . A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165–172.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, . A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609–2617.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, . Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–2498.
   PubMed Web of Science ®Google Scholar
• Blade J, Samson D, Reece D, . Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115–1123.
   PubMed Web of Science ®Google Scholar
• Hoaglin DC, Mosteller F, Tukey JW. Understanding robust and exploratory data analysis. New York: John Wiley Sons; 2000.
   Google Scholar
• Hashmi M, Kojouri K, Yang J, . Prognostic significance of BCL-2 expression in patients with multiple myeloma. Blood 2004;104 (Suppl. 1): Abstract 4840.
   Google Scholar
• Largo C, Alvarez S, Saez B, . Identification of overexpressed genes in frequently gained/amplified chromosome regions in multiple myeloma. Haematologica 2006;91:184–191.
   PubMed Web of Science ®Google Scholar
• Wellek S. Testing statistical hypotheses of equivalence. Boca Raton, FL: Chapman Hall/CRC; 2003.
   Google Scholar
• Hintze JL, Nelson RD. Violin plots: a box plot-density trace synergism. Am Stat 1998;52:181–184.
   Web of Science ®Google Scholar
• Ambroise C, McLachlan GJ. Selection bias in gene extraction on the basis of microarray gene-expression data. Proc Natl Acad Sci USA 2002;99:6562–6566.
   PubMed Web of Science ®Google Scholar
• Bair E, Tibshirani R. Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2004;2:E108.
   PubMed Web of Science ®Google Scholar
• Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005;23:7332–7341.
   PubMed Web of Science ®Google Scholar
• Puthier D, Pellat-Deceunynck C, Barille S, . Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy. Leukemia 1999;13: 289–294.
   PubMed Web of Science ®Google Scholar
• Sangfelt O, Osterborg A, Grander D, . Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein. Int J Cancer 1995;63:190–192.
   PubMed Web of Science ®Google Scholar
• Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590–8607.
   PubMed Web of Science ®Google Scholar
• Harada N, Hata H, Yoshida M, . Expression of Bcl-2 family of proteins in fresh myeloma cells. Leukemia 1998;12:1817–1820.
   PubMed Web of Science ®Google Scholar
• Kline MP, Rajkumar SV, Timm MM, . ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 2007;21:1549–1560.
   PubMed Web of Science ®Google Scholar
• Kline MP, Rajkumar SV, Timm MM, . R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. Exp Hematol 2008;36:568–576.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Velankar M, Brahmandam M, . A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007;26:2374–2380.
   PubMed Web of Science ®Google Scholar
• Winter JN, Weller EA, Horning SJ, . Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006;107:4207–4213.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Kaufman JL, Mehta J, . Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007;109: 2604–2606.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, . Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 2006;106: 1316–1319.
   PubMed Web of Science ®Google Scholar